Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,895 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Defining overactive bladder as hypersensitivity.
Yamaguchi O, Honda K, Nomiya M, Shishido K, Kakizaki H, Tanaka H, Yamanishi T, Homma Y, Takeda M, Araki I, Obara K, Nishizawa O, Igawa Y, Goto M, Yokoyama O, Seki N, Takei M, Yoshida M. Yamaguchi O, et al. Among authors: yoshida m. Neurourol Urodyn. 2007 Oct;26(6 Suppl):904-7. doi: 10.1002/nau.20482. Neurourol Urodyn. 2007. PMID: 17663416 Review.
Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M; Japanese Solifenacin Study Group. Yamaguchi O, et al. Among authors: yoshida m. BJU Int. 2007 Sep;100(3):579-87. doi: 10.1111/j.1464-410X.2007.07031.x. BJU Int. 2007. PMID: 17669143 Clinical Trial.
Clinical guidelines for overactive bladder.
Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, Kakizaki H, Obara K, Gotoh M, Igawa Y, Seki N, Yoshida M; Neurogenic Bladder Society. Yamaguchi O, et al. Among authors: yoshida m. Int J Urol. 2009 Feb;16(2):126-42. doi: 10.1111/j.1442-2042.2008.02177.x. Int J Urol. 2009. PMID: 19228224 No abstract available.
Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.
Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S, Masumori N, Nagai S, Minemura K. Yoshida M, et al. Neurourol Urodyn. 2021 Aug;40(6):1651-1660. doi: 10.1002/nau.24732. Epub 2021 Jun 17. Neurourol Urodyn. 2021. PMID: 34139038 Free PMC article. Clinical Trial.
Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction.
Takeda M, Homma Y, Araki I, Kakizaki H, Yamanishi T, Yokota T, Gotoh M, Igawa Y, Seki N, Takei M, Yoshida M, Sugaya K, Nishizawa O; Japanese Naftopidil Neurogenic Lower Urinary Tract Dysfunction Study Group. Takeda M, et al. Among authors: yoshida m. BJU Int. 2011 Jul;108(1):100-7. doi: 10.1111/j.1464-410X.2010.09682.x. Epub 2010 Nov 9. BJU Int. 2011. PMID: 21062392 Clinical Trial.
10,895 results
You have reached the last available page of results. Please see the User Guide for more information.